Michael Hunt, chief financial officer for the stem cell specialist () updates Proactive on two of their clinical programmes.
Hunt says they're preparing to meet with US regulators on plans for a phase III trial of its treatment for victims of stroke.
He also mentions that a new formulation of their human retinal progenitor cell which is being trialled to treat degenerative diseases of the retina, represents a major step forward for them.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...
FOR OUR FULL DISCLAIMER CLICK HERE